Physician profile

Jayant Dey

Endocrinology, Diabetes & Metabolism · Tupelo, MS

NPI 1740251941

$1,482.19

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $193.17 2019-2020
Sanofi-Aventis U.S. LLC $183.41 2019-2020
Novo Nordisk INC $178.94 2019-2020
Amgen INC. $115.78 2019-2020
Shire North American Group INC $112.85 2019
Merck Sharp & Dohme LLC $85.26 2019
Corcept Therapeutics $83.87 2019-2020
Insulet Corporation $56.85 2019-2020
Ultragenyx Pharmaceutical INC. $53.78 2019-2020
Medtronic Minimed, INC. $51.49 2019
Dexcom, INC. $44.73 2019-2020
Amarin Pharma, INC. $44.18 2019
Eisai INC. $42.94 2019
Astrazeneca Pharmaceuticals Lp $40.64 2019
Regeneron Healthcare Solutions, INC. $38.37 2019
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $33.68 2019
Kowa Pharmaceuticals America, INC. $26.01 2019
Boehringer Ingelheim Pharmaceuticals, INC. $25.58 2019
Vivus LLC $20.33 2019
Mannkind Corporation $18.35 2019
Pfizer INC. $17.80 2019
Abbvie INC. $14.18 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jayant Dey

$1,482.19

in general payments reported 2019-2025

Years
2019-2020
Top company
Lilly USA, LLC

https://glasscript.com/doctor/169391/jayant-dey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.